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  Dilantin (DPH) is a common anticonvulsant drug used to prevent seizures. 
It is known to be a human teratogen causing fetal hydantoin syndrome (FHS).  
FHS is characterized by multiple developmental and growth related abnormalities 
and mental retardation. Previous studies demonstrated that DPH slowed growth 
and division in preimplantation mouse embryos in vivo  and  in vitro.  DHP 
exposure in utero decreased the crown to rump length and weight of 25-35% of 
embryos and reduced the rate of endochondral bone conversion from cartilage.  
In vitro preimplantation mouse embryos treated with DPH at 5, 10 and 20 µg/ml 
showed a reduction of 25-35% in their development, and block at 2-cell or 3-4-
cell stages. These embryos also showed a prolonged DNA synthesis (S) phase 
during the second cell cycle.  Nuclear localization and concentration levels of  
ii 
 
cyclin A , the S phase cyclin, were also altered in vivo in 2-cell DPH treated 
embryos compared with NaOH control embryos during G1, S phase and G2 of 
the first, second and third cell cycles.  DPH altered patterns of expression of 
cyclin A were associated with cell cycle disregulation during preimplantation 
development.  The purpose of the current study was to determine whether DPH 
also affects the concentration of DNA pol δ catalytic subunit in 2-cell 
preimplantation mouse embryos at G1 and S phases, thus delaying DNA 
synthesis and contributing to FHS.  Immunofluorescence and confocal 
microscopy were used as tools to determine relative levels and distribution of 
DNA pol δ (for consistency with text) in the cytoplasm and the nuclei of DPH and 
NaOH treated 2-cell embryos at G1 and S phase of the second cell cycle.  DPH 
decreased DNA pol δdelta total embryo and nuclear levels by 43% and 36%, 
respectively, in G1 compared with NaOH controls.  Similarly, nuclear levels of 
DNA pol δ in DPH embryos in S phase near the G2 transition of the second cell 
cycle increased to 144% of NaOH control levels; there was not a statistically 
significant difference between total embryonic levels of late S phase DNA pol δ in 
DPH and NaOH treated control embryos.  The results indicated that DPH affects 
the levels of DNA pol δduring G1 and S phase near the G2 transition of the 
second cell cycle in preimplantation mouse embryos.  The significant alteration in 
the levels of DNA pol δ during S phase and its probable consequent altered 
polymerase activity could contribute to an explanation for the extension of S 
phase in preimplantation embryos observed by Blosser and Chatot.  Even more,  
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the alteration in the levels of DNA pol δ and potentially in its exonuclease activity 
could lead to an increase in the rate of mismatches and mutations suggesting a 
likely explanation for some features of FHS. 
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INTRODUCTION 
 
Dilantin (DPH), one of the most widely prescribed anticonvulsant drugs, is 
a teratogen responsible for fetal hydantoin syndrome (FHS) (Oguni and Osawa, 
2004).  FHS is characterized by abnormal development of human offspring 
including low birth weight, mental retardation, and skeletal anomalies.  The 
effects of DPH on embryological development and cell cycle progression in the 
preimplantation mouse embryo have been studied in Dr. Chatot’s lab for a 
number of years.  The first studies with DPH in this lab indicated that the drug 
slowed the growth and division of preimplantation mouse embryos both in vivo 
and in vitro (Wolter and Chatot,1993; Gonzalez and Chatot, 1994; Blosser and 
Chatot, 2003).  Wolter and Chatot (1993) demonstrated that approximately 25-
35% of NSA x B6SJL/F1J embryos exposed to DPH in utero during the first five 
days of development had decreased crown to rump length and weight. Gonzales 
and Chatot (1994) observed a reduction in the rate of endochondral bone 
conversion from cartilage particularly in the limbs in embryos exposed to DPH in 
utero. Blosser and Chatot (2003) found a reduction of 25-35% in cultured one-
cell embryo development with DPH treatment of 5, 10 and 20 µg/ml.  They also 
observed development only to the 2-cell or 3-4-cell stage rather than to the 2 
 
blastocyst stage in seriously affected embryos. Blosser’s study also 
demonstrated an extended DNA synthesis (S) phase during the second cell cycle 
in DPH-treated embryos compared to NaOH vehicle controls.   
Recent research (Tolle and Chatot, 2009) indicated that DPH treatment 
altered the developmental patterns of cyclin A expression in preimplantation 
mouse embryos in vivo.  Cyclin A is a protein necessary for cell cycle regulation 
especially at the DNA synthesis (S) phase.  DPH treatment decreased the 
expression levels of cyclin A 1.28 fold during the S phase of the second cell cycle 
and 1.67 fold in G1 of the third cell cycle in preimplantation mouse embryos in 
vivo compared with NaOH treated vehicle control.  In contrast, DPH treatment 
increased the expression levels of cyclin A during G1 of the second cell cycle by 
1.55 fold and during G2 of the same cycle by 1.39 fold compared with the NaOH 
treated vehicle controls.   
When compared with control embryos, DPH treatment altered nuclear 
localization of cyclin A causing early entry of cyclin A into the nucleus of a 
considerable proportion of embryos during G1 of the second (83% vs 23%) and 
third cell cycles (93% vs 63%) (Tolle & Chatot, 2009).  These data suggested 
that DPH alteration of cyclin A expression and nuclear localization generates cell 
cycle deregulation, in particular during S phase of the 2
nd cell cycle, which would 
affect normal development of preimplantation mouse embryos in vivo and could 
contribute to FHS. 3 
 
Some authors affirm that cyclin A is directly associated with DNA 
replication (Bashir et al., 2000).  Evidence from in vitro  assays indicates that 
cyclin  A  activates  the  DNA  polymerase  δ-dependent elongation machinery in 
vitro.  Using a parvovirus DNA replication model, Bashir et al. (2000) suggested 
that cyclin A may stimulate complementary strand synthesis through activation of 
its associated kinase, Cdk2.   
The current study will focus on the expression level of the DNA 
polymerase δ subunit following in vivo DPH treatment.  Embryos will be analyzed 
at G1 and S phases of the second cell cycle using Western blot analysis in order 
to evaluate the relationships between changes in DNA polymerase expression 
and DPH induced changes in cyclin A.  
Hypothesis Statement 
The hypothesis for this study is that DPH induced alteration of 
developmental patterns of cyclin A expression during S phase of the second cell 
cycle  will  alter  DNA  polymerase  δ  expression  and  in  turn,  activity  in 
preimplantation mouse embryos, thus altering the elongation phase of DNA 
synthesis.  Cyclin A levels at G1 are high (Tolle and Chatot, 2009) and S phase 
is delayed during the second cell cycle (Blosser and Chatot, 2003) in DPH 
treated embryos.  Bashir et al. (2000)  indicated  that  DNA  polymerase  α-
dependent (Pol α) initiation of SV40 DNA replication is inhibited by cyclin A/cdk2.  
However,  they  also  suggested  that  Pol  δ-dependent elongation could be 
stimulated by cyclin A.  We initially speculate that high levels of cyclin A during 4 
 
G1 of the second cell cycle in DPH treated embryos inhibited Pol α-dependent 
initiation, thus delaying S phase.  Moreover, decreased levels of cyclin A during 
S phase of the second cell cycle could delay DNA pol δ-dependent elongation, 
thus making S phase longer compared with control embryos as reported by 
Blosser and Chatot (2003).   
Significance 
This research will provide a better understanding of DPH teratogenicity 
and its consequent alterations in embryo development as well as its influence in 
the appearance of FHS in offspring of pregnant women.  The results obtained will 
be a source of new information that could potentially be useful in the design of 
drugs to provide more effective and accurate treatments for epilepsy during 
pregnancy.  Finally, the data generated will yield an improved understanding of 
the basics of cell cycle regulation and DNA synthesis in preimplantation mouse 
embryos. 5 
 
LITERATURE REVIEW 
 
DPH Metabolism and Teratogenicity 
The first description of the association between prenatal exposure to anti-
epileptic drugs and major congenital malformations was provided by Müller-
Kuppers (Oguni and Osawa, 2004).  He described a boy with microcephalus and 
cleft palate who was born to a mother taking mephenytoin (phenytoin, DPH) for 
epilepsy.  Since this first report the congenital malformations of children born 
from women with epilepsy and taking phenytoin/DPH has received considerable 
attention. The particular clusters of anomalies observed in these offspring were 
termed “fetal hydantoin syndrome” (FHS) by Hanson and Smith (1975). 
DPH teratogenicity is attributed to intermediary metabolites which are 
formed as a product of the biotransformation of this compound (Buehler et al., 
1990). Cytochrome P-450 monooxygenases metabolize DPH to various oxidized 
products (Strickler et al., 1985),the most important product of which is thought to 
be the arene oxide metabolite.  This oxidative intermediate, called an epoxide, is 
indicated as the primary teratogenic agent of DPH (Strickler et al.,  1985).  
Epoxides have an oxygen bridge, making them very reactive, and they are able 
to bind covalently to the embryo or fetal nucleic acids, resulting in a high risk of 6 
 
abnormal development during the early stages of embryogenesis (Figure 1 a and 
b) 
                       
                 Figure 1. Chemical structure of DPH and metabolites.  (Chatot lab)  
  However, the rate of detoxification of the reactive epoxide into inactive 
metabolites (Figure 1 d-f) by the enzyme epoxide hydrolase determines the 
susceptibility of a particular embryo to birth defects induced by DPH or any 
antiepileptic drug (AED) (Buehler et al. 1990).  Strickler et al. (1985) suggested 
that a genetic defect in epoxide hydrolase, the enzyme which detoxifies reactive 7 
 
epoxide, increases the risk of having children with FHS in pregnant women using 
DPH. 
Buehler et al. (1990) suggested that epoxide hydrolase activity is 
regulated by a gene with two alleles.  Persons who are homozygous (having two 
recessive alleles) will have low epoxide hydrolase activity and will be at high risk 
for FHS.  However, people who are homozygous (having two dominant alleles) 
will express very high enzyme activity and will have no risk of FHS.  Finally, 
heterozygous individuals will have an intermediate enzyme-activity profile and 
low or no risk. 
  Teratogenicity of DPH (phenytoin; diphenylhydantoin) has been 
demonstrated in a series of experiments performed in animals in vitro and in vivo 
(Shanks et al., 1989).  To understand the embryotoxicity of DPH, studies were 
performed using enzymatic bioactivation in a murine embryo culture model. The 
results suggested that the electron transport system of cytochrome P-450 which 
includes a group of enzymes involved in drug metabolism catalyzes the 
activation of phenytoin to a highly reactive arene oxide intermediate that is the 
putative proximal teratogen.  If the arene oxide is not detoxified, it could bind 
covalently to important fetal cellular macromolecules that could interfere with the 
normal development of the fetus.  In this experiment, an exogenous P-450 
system was administered to the embryo culture which enhanced the bioactivation 
of phenytoin; the bioactivation was verified and quantified by the detection of 
irreversible radiolabeled DPH bounded to embryonic proteins during the 9
th and 8 
 
10
th  days of development. Results indicated that mouse embryos could also 
bioactivate DPH endogenously promoting alterations in embryo development due 
to the presence of the arene oxide.  In addition, Shanks et al. (1989) implicated 
an influence of the maternal system in DPH teratogenicity.  This effect may not 
have involved the arene oxide directly since it is very highly reactive and would 
not likely reach the fetus if produced maternally.  The maternal influence might 
have involved folate deficiency as DPH is known to cause reduced folate levels 
in treated epileptics.  However, Hernandez-Diaz et al. (2000) compared two 
groups of women: one group of 100 women who were on anticonvulsant drugs 
supplemented with folate during pregnancy, and another group of 8,000 women 
who were on anticonvulsant drugs alone.  The results from this study suggested 
that there was no significant correlation between folic acid levels and the 
decrease in the risk of malformations. 
Preimplantation Mouse Development 
The preimplantation stage of development occurs after fertilization of the 
oocyte which takes place in the ampulla of the oviduct (Sakkas and Vassalli, 
2008).  During preimplantation the mouse embryo will travel through the oviduct 
over the course of 4 days until it reaches the uterus for final implantation.   
Preimplantation development is characterized by a series of asynchronous cell 
divisions until the blastocyst is formed (16-32 cells).  At the late blastocyst stage 
the embryo hatches from the zona pellucida and implants in the uterus. To 9 
 
develop from the 1-cell stage to the blastocyst stage preimplantation mouse 
embryos take approximately three and a half days (Figure 2).   
 
 
Figure 2.  Stages of mouse development during preimplantation.(Chatot lab)  
 
During preimplantation development, the embryo goes through different 
metabolic phases including changes in protein synthesis, amino acid uptake and 
energy requirements (Sakkas and Vassalli, 2008).  For example, the embryo 
uses lactate, pyruvate, and glutamine as energy sources until the 8-16 cell stage 
when glycolysis activation shifts the primary energy substrate to glucose (Wales 
and Whittingham 1973, Leese and Barton, 1984; Chatot et al., 1990; Martin and 
Leese, 1995;).   10 
 
One of the most important changes in early mouse embryo development 
is zygotic gene activation (ZGA) (Minami et al., 2007).  This event refers to the 
shift from the maternal developmental program, controlled by maternally inherited 
transcripts and proteins stored in the oocyte, to the embryonic developmental 
program, characterized by embryonic transcripts and proteins. In mouse 
embryos, ZGA occurs during the late 1-cell and early to mid 2-cell stage, 
corresponding with the very long 2
nd cell cycle.  Maternal zygotic transition has 
three components: Degradation of maternally inherited transcripts; replacement 
of maternally inherited transcripts with embryonic transcripts (for example 
housekeeping gene transcripts), and;  generation of new embryo-specific 
transcripts (alterations in gene expression from inactive to active zygotic genes).  
The Cell Cycle  
The cell cycle is a process characterized by the formation of two 
equivalent daughter cells from the division of one parental cell (Becker et al., 
2009).  In eukaryotes the cell cycle  is divided into G1, S, and G2, which 
constitute interphase, and finally M phase or mitosis (cell division).  Interphase 
includes the period of time between the end of one mitosis to the start of the next 
one (Lewin, 2004).  Cells in G1 phase (or gap 1) are active in RNA and protein 
synthesis after being released from mitosis.  In a typical somatic cell, this period 
varies from 6-12 hours. DNA replication starts at the transition from G1 phase to 
S phase.  S phase lasts until the complete genome is duplicated and takes 
approximately 6-8 hours.  G2 phase (or gap 2) is generally the shortest period 11 
 
and lasts from the end of S phase until mitosis; here the cells possess two diploid 
sets of chromosomes.  G2 is a time when replication of organelles like 
mitochondria and synthesis of extra membranes, like the Golgi apparatus and 
endoplasmic reticulum occur in order to prepare for cell division.  M phase is very 
brief and lasts usually less than 1 hour. This sequence of phases is repeated 
cyclically every 18-24 hours  in somatic animal cells.  
Cell cycle duration in the preimplantation mouse embryo varies.  These 
variations can be linked to particular events that occur during this period 
including embryonic genome activation, which results in a lengthened cell cycle 
from the 2- to 4- cell stage (Sakkas and Vassalli, 2008).  The length of the G2 
and M phases of the second cell cycle depends on mouse strain specificity which 
leads to differences in the duration of the 2-to 4-cell cycle. However, in a general 
sense in the preimplantation mouse embryo, G1 phase is 3-8 hours long, S 
phase is 6 hours, and G2/M phase is 6 hours during the first cell cycle, which 
totals 15-23 hours (Krishna and Generoso, 1977). During the second cell cycle, 
G1 is 1.3 hours long, S is 6.1 hours long, and G2/M is 15.4 hours long, totaling 
22.8 hours although in some strains the second cell cycle can last up to a total of 
30 hours (Sawicki et al., 1978).  For the third cell cycle, G1 is 1.6 hours, S is 7.4 
hours, and G2 is 0.5 hours, totaling 9.5 hours. 
Cell cycle regulation: cyclin and cyclin dependent kinase expression  
Cell division is an important process which is highly regulated by many 
endogenous factors (Waclaw and Chatot, 2004). Progression through the 12 
 
different phases of the cell cycle in eukaryotes is controlled by sets of specific 
regulatory proteins, cyclins and cyclin-dependent kinases (cdks) (Becker et al., 
2009).  The primary function of the  cyclins is to bind and activate cdks.  The 
interaction between cyclins and cdks is necessary for each phase of the cell 
cycle to progress into the next one, i.e. G1 to S, S to G2, G2 to M, etc. Cyclins 
activate cdks to make cdks able to phosphorylate target proteins necessary for 
the regulation of the cell cycle.  Cyclins are phase-specific and undergo a cycle 
of synthesis and degradation at specific points in the cell cycle.  Once cyclins are 
degraded, cdks are inactivated.  Cyclins are specific for regulation of the two 
most important checkpoints in the cell cycle, G1 before entry into S phase and at 
the last part of G2 during entry into mitosis.  These are called G1/S cyclins and 
G2/M (mitotic) cyclins. 
Cyclin D and E are G1/S cyclins (Waclaw and Chatot, 2004).  Type D 
cyclins associate with cdk 4 or cdk 6 to form functional enzyme complexes.   
Cyclin E activates cdk2 during the end of G1.  Cyclins A and B are G2/M 
regulators.  Cyclin A associates with cdk2 during S phase but during G1, both 
cyclins A and B associate with cdk1 (Figure 3). 
 13 
 
                      
Figure 3.  Expression of cyclins and cdks during the typical somatic     
cell cycle (Santa Cruz Biotechnology, Inc.). 
 
  Patterns of expression of cyclins/cdks in preimplantation mouse embryo 
are consistent in some cases with cyclin expression in somatic cells, but in other 
cases expression  patterns are exclusive to cleavage-stage embryos in 
relationship to maternal storage of RNA and zygotic gene activation (Waclaw and 
Chatot, 2004).  Using indirect immunofluorescence with antibodies against 
cyclins D, E, A and B1, Waclaw and Chatot (2004) demonstrated that Cyclin D is 
low in the first cell cycle but establishes a somatic like expression pattern in cell 
cycles 2 and 3.  Cyclin E peaked in expression at G1 of the first and third cell 
cycles but was found at moderate levels throughout the second cell cycle 
probably because of maternal product degradation and zygotic gene activation.  14 
 
Cyclin A was present at moderate levels through cell cycles 1 and 2 but began to 
establish the somatic patterns of expression in the third cell cycle increasing in S 
phase and peaking in G2.  Cyclin B1 was found in lower than expected levels in 
its normal G2 phase but was present in high levels in G1 as well in all 3 cell 
cycles examined (Figure 3). 
Cyclin A 
 The in vivo pattern of cyclin A expression during the second cell cycle in 
the preimplantation mouse embryo is not similar to that of typical somatic cells.  
Waclaw and Chatot (2004) reported cyclin A levels were moderate throughout 
the two first cell cycles, becoming more like somatic cells only in the third cell 
cycle.  Levels of Cdk2, the cyclin dependent kinase associated with cyclin A 
during S phase, were constant during G1 and S phases.  
Cyclin A functions both during S phase as well as G2.  During s phase, 
Bashir et al. (2000) affirmed that cyclin A activates the  DNA  polymerase  δ-
dependent elongation machinery in vitro.  They  concluded that cyclin A is 
necessary for the activation of the synthesis of the complementary strand in a 
parvovirus DNA replication model.  Cyclin A activation of complementary strand 
synthesis  in vitro was determined by the ability of A9 (mouse fibroblasts) to 
convert single-stranded DNA of minute virus of mice (MVM) into the double-
stranded form.  The most relevant conclusion of Bashir’s experiment was that 
cyclin A could stimulate DNA synthesis by DNA Pol δ-dependent activation.  Pol 
δ-dependent DNA synthesis is responsible for the elongation of DNA strands 15 
 
during DNA synthesis in S phase.   In addition to the relationship between Pol δ-
dependent DNA elongation and cyclin A, Voitenleitner et al. (1997) reported that 
cyclin A/cdk2 inhibited Pol α-dependent initiation of SV40 DNA replication.  Thus, 
cyclin A, in its double role of inhibition of Pol α-dependent initiation and activation 
of Pol δ-driven elongation, probably contributes to the change from initiation to 
strand elongation, during DNA synthesis. 
DNA polymerases 
DNA polymerases are enzymes necessary for the synthesis, repair and 
recombination of the DNA, as well as bypassing  of damage in DNA (Hübscher et 
al., 2002).  Thus, DNA polymerases maintain the integrity of the genome during 
cell division.  
  DNA polymerases have been grouped into five families based on 
sequence homology and structural similarities (Hübscher et al., 2002).  The 
families are A, B, C, X and Y.  Family B represents the eukaryotic replicative 
polymerases including pol α, pol δ and pol ε.  All eukaryotic polymerases are 
hetero-multimers composed of a large catalytic subunit and a number of smaller 
subunits.  The latter are involved in the stabilization of the catalytic subunit, in 
cell-cycle regulation, in protein-protein interactions, and in check-point roles. 
  Although polymerases from different families differ in some aspects of 
their structure, they share several features (Hübscher et al., 2002).  All of them 
have conformational structures that resemble a human right hand with three 
different domains called palm, thumb and fingers. 16 
 
DNA Pol α  
DNA pol α, also called pol α/primase, is a heterotetrameric enzyme with 4 
subunits: p180 subunit (catalytic), p68 subunit (responsible for protein-protein 
interactions), p55 and p48 subunits (primase activity) (Hübscher et al., 2002).  
Pol α functions to initiate DNA synthesis de novo using a RNA/DNA primer in 
association with the initiation complex at the DNA origin of replication and primes 
Okazaki fragments (Pavlov and Shcherbakova, 2010) on the lagging strand of 
the replication fork. 
DNA Pol α Switch to Pol δ 
The replacement of pol α/primase by pol δ holoenzyme is called pol switch 
(Hübscher et al., 2002).  This substitution depends on the synthesis of the 
RNA/DNA  primer  by  pol  α.    This  switch  allows  the  change  from  initiation  to 
elongation during the DNA synthesis. 
DNA Pol δ  
DNA  pol  δ  is  a  high  molecular  weight  complex  of  four subunits: p125 
subunit (catalytic), p55 subunit (structural), p66 subunit (proliferating cell nuclear 
antigen [PCNA] interaction), and p12 subunit (protein-protein interactions) 
(Hübscher et al., 2002).   The catalytic subunit is the largest polypeptide and 
possesses DNA polymerase activity and 3’-5’ exonuclease proofreading 
properties (Pavlov and Shcherbakova, 2010); it has protein-protein interaction 
sites and a motif for PCNA-binding (Figure 4).   17 
 
                
Figure 4.  DNA polymerase delta catalytic subunit: Polymerase and 
Exonuclease domains  (www.google.images) 
 
The second subunit, p55, helps to stabilize the catalytic subunit and to 
hold the third subunit, p66 (Pavlov and Shcherbakova, 2010).  Third subunit has 
a PCNA-binding motif and another functional domain which interacts with pol α.  
This subunit is associated with the regulation of error-prone translesion 
synthesis.  The role of the fourth subunit, p12, is not well understood yet, but 
experiments in humans suggest that it could be involved in the response of pol δ 
to DNA damage (Pavlov and Shcherbakoba, 2010).  Zhang et al. (2007) 
performed experiments in UV-treated cells generating damage intended to 
degrade the p12 subunit of pol δ transforming the tetramer pol δ into a trimer.  
However, pol δ3-12 exhibited substantial level of activity, which suggests that it 
could be able to perform extension of the lagging strand in vivo and participate in 
the process of DNA repair in vivo. 18 
 
The main role of Pol δ is to elongate and coordinate both leading and 
lagging strand synthesis from a RNA/DNA primer through its association with 
(PCNA),  which  enhances  pol  δ  processivity.    The  traditional  model  proposes 
three replicative pols in which pol α initiates DNA synthesis, pol δ elongates the 
lagging strand and pol ε extends the leading strand (Pavlov and Shcherbakova, 
2010).  The replication of the lagging strand is characterized by the presence of 
the Okazaki fragments, which are small pieces of DNA of approximately 200 bp 
(Hubscher et al., 2002). 
DNA Pol ε 
DNA  Pol  ε  is  composed  of  four  subunits:  p261  subunit  (catalytic),  p59 
subunit (multimerization), p17 subunit (protein-protein interactions), and p12 
subunit (protein-protein interactions) in humans (Hübscher et al., 2002). The two 
smaller subunits interact with the two larger subunits forming the 
heterotetrameric enzyme.   Pol ε is necessary for DNA replication and is involved 
in the quality control of that process.  S. cerevisiae and S. pombe mutants with 
deletions at the N-terminus of pol ε are viable, but accumulate DNA damage and 
require the expression of the genes rad3, hus1  and ck1 which participate as 
checkpoint genes for DNA synthesis to allow replication (Feng and  D’Urso, 
2001). This data indicates that pol ε is necessary for DNA replication but not 
indispensable (Pavlov et al. 2004), and that it can be replaced as a replicase but 
not in its function as a checkpoint enzyme (Hubscher et al., 2002). 
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DNA polymerases and the Replication Fork: Traditional and New M 
Pavlov and Shcherbakova (2010) gathered and analyzed all available 
experimental data related to the replicative DNA polymerases and examined 
which part of the data could be explained with the traditional model of the 
replication fork and which part was in conflict with it.  They realized that in the 
traditional model the role of pol δ was underestimated and presented a new one 
which integrates both data in favor and data against the traditional one strand-
one DNA polymerase model. 
The traditional model proposes that each replicative DNA polymerase has 
a  role  in  the  DNA  synthesis:  pol  α  initiation,  pol  δ  elongation  of  the  lagging 
strands via Okazaki fragments and pol ε elongation of the leading strand (Figure 
5). 
 
Figure 5. Representations of the traditional (standard fork) and the 
new model (Alternate fork) of DNA replication.  (From Burgers, 2009)  20 
 
 
Inconsistency of the one strand-one DNA polymerase model 
Several lines of evidence have recently suggested that there are 
inconsistencies in the traditional one strand-one DNA Pol model (Pavlov et 
Shcherbakova, 2010). Mutants with deletions of the active site of pol ε in yeast 
shows that they can survive without pol ε (Pavlov et al. 2004) this indicates that 
pol ε participates normally in the replication fork.  N terminal deletion mutants of 
pol ε lack polymerase activity and are most likely involved recruiting proteins to 
the replication complex since the C terminus is functional.  However, the absence 
of polymerase activity could be compensated for by pol δ.   Mutants with 
deletions in a single amino acid in the small subunit Dpb4p of pol ε are not viable 
(Hubscher et al. 2002).  Mutants with point mutations in the C terminal of the 
catalytic subunit of pol ε are lethal (Pavlov and Shcherbakova, 2010) due to 
damage in the cysteine-rich region of the C terminal which is associated with S 
phase checkpoint (Dua et al. 1999).  Mutants affected with pol δ deletions suffer 
stronger effects than mutants affected with analog alterations in pol ε (Pavlov et 
Shcherbakova, 2010).   Experiments have shown that deletions in the catalytic 
subunit of pol δ are fatal (Pavlov et Shcherbakova, 2010).  Pol δ and ε 3’-5’ 
exonuclease domains compete for repair of the same group of replication errors 
(Pavlov et Shcherbakova, 2010).  Experiments using DNA damage-induced 
mutagenesis in yeast suggest that pol δ may be involved in the recruitment of 
translesion synthesis (TLS) pols to bypass DNA lesions, regardless the strand 
where the lesion is present (Pavlov et Shcherbakova, 2010).  Therefore, in these 21 
 
cases, pol δ would be associated with both the leading and lagging strand.  In 
addition, observations of in vitro activities of pol δ and ε in yeast demonstrate that 
pol ε is less effective than pol δ, thus indirectly contradicting the idea that pol ε is 
a major replicase and supporting the possibility that pol δ could in fact replicate 
both the leading and lagging strands (Pavlov et Shcherbakova, 2010).  
The new suggested model, inspired by the original Morrison/Sugino lab 
model (Figure 5) and in recent studies of the DNA polymerases involved in the 
DNA replication, proposes that DNA pol δ participates in the elongation of the 
lagging strand and in the elongation of the leading strand too, after the elongation 
synthesis of the leading strand is started by pol ε near the origins of replication 
following pol α initiation (Pavlov and Shcherbakova, 2010).  These DNA 
polymerase interactions have been described before as an alternative replication 
fork model in cases of the lack of functional pol ε or after restarting replication if 
the traditional fork model failed.   
  However, Pavlov and Shcherbakova (2010) propose that this is not an 
alternative mode of action of the fork, but the normal mechanism. Genetic studies 
confirm that the model of the three pols Morrison/Sugino traditional model occurs 
in the vicinity of the origin of replication. 
Pavlov and Shcherbakova (2010) suggest that this model corroborates the 
observations that mutations affecting DNA pol δ have stronger impact on strain 
growth and genome stability than similar mutations affecting DNA pol ε.  The 
model provides an explanation for experiments in which competition between pol 22 
 
δ and ε 3’-5’ exonuclease domains for the same group of replication defects is 
verified, indicating that both can enzymes correct each other mistakes.    
Finally, Pavlov and Shcherbakoba  (2010) propose a new pol, zeta (ζ), 
which could assist the three main replicative polymerases during the DNA 
synthesis, although is dispensable for replication and normal growth in yeast.  ζ 
is also associated with the extension of mismatched primers and other defects 
which are not extended efficiently by the replicative pols. 
DNA Damage and Alteration of the Replication Dynamics: Progression of 
the Replication Fork 
Merrick et al. (2004) performed experiments using HeLa cells to 
understand the dynamics of DNA replication when DNA is damaged or affected 
by different toxigenic substances or agents.  DNA damage experiments were 
performed with different treatments: methyl methane sulfonate (MMS; an 
alkylating agent) produced a general decrease in the movement of the replication 
fork, stalling of many forks for extended periods of time and blocked the firing of 
the origin of replication for longer times than ionizing radiation; Ionizing Radiation 
(IR) produced temporal blocking of origin firing; and hydroxyurea (HU; an 
antineoplastic DNA synthesis inhibitor) produced reduction of origin firing.  
DNA pols and Cell-cycle Regulation 
  DNA polymerases and their accessory factors (PCNA and RFC) can act 
as cell cycle regulators stimulating S-phase arrest due to DNA damage 23 
 
(Hübscher et al., 2002).  DNA polymerases also can be targets of inhibitory 
molecules generated by external stimuli, for example UV light, which produces a 
block in S-phase progression to allow DNA repair or apoptosis. 
During the cell cycle DNA polymerases can be phosphorylated by cyclin-
dependent  kinases  (Lemmens  et  al.,  2008).    Pol  δ  is  phosphorylated  more 
actively during the S phase.  Lemmens et al. (2008) reported that the p66 subunit 
of DNA polymerase δ could be phosphorylated by Cdk/cyclin complexes in vitro 
which blocks PCNA binding.    They suggested that this phosphorylation could 
affect replisome assembly in HeLa cells when S phase begins. A study of 
physical interactions between pol δ and cyclin-dependent kinases was reported 
and the interaction domains were mapped (Hübscher et al. 2002).   
The current study characterizes effects of the anticonvulsant drug DPH on 
the expression of DNA  Pol  δ,  perhaps  the  major  DNA  pol  in  the  cell.  
Preimplantation mouse embryos treated either with NaOH vehicle control or DPH 
exhibit interesting differences in their patterns of expression in G1 and S phase 
of the second cell cycle which may contribute to the extended second cell cycle S 
phase demonstrated in DPH treated embryos by Blosser and Chatot (2003). 24 
 
MATERIALS AND METHODS 
 
 
Immunofluorescent staining and confocal microscopy  was performed to 
determine both relative distribution and concentration of DNA polymerase δ in 
DPH and sodium hydroxide (NaOH) vehicle control treated preimplantation 2-cell 
mouse embryos in vivo during G1 and S phases of the second cell cycle.   
Induction of Superovulation and Dilantin Treatment 
NSA female mice (Harlan Sprague Darley, Indianapolis, IN and lab 
breeding colony) were superovulated to obtain enough embryos for statistical 
analysis purposes by intraperitoneally injecting 10 International Units (IU) of 
pregnant Mare Serum Gonadotropin (PMS) (EMD Chemicals/Cal Biochem, 
Gibbstown, NJ) dissolved in sterile tissue culture water at 1000 IU per mL (Sigma 
Chemical Co. St. Louis, MO) to generate the maturation of multiple follicles.  The 
PMS dose was followed, 48 hours later, by injection of 5 IU of Human Chorionic 
Gonadotropin (hCG) (Sigma Chemical, St. Louis, MO) dissolved in sterile tissue 
culture water at 500 IU per mL to cause synchronous ovulation.  Superovulated 
NSA female mice were mated overnight with B6SJLF1/J males (Jackson 
Laboratories, Bar Harbor, ME).   25 
 
NSA female mice were injected with DPH (55 mg/kg) or vehicle control 
(0.01 N NaOH at 0.1 mL per 10 g body weight) at 11: 00 - 11:30 a.m. on the 
morning after mating. The dose for DPH treatment was 55 mg per kg of body 
weight in the mouse.  This dose has been estimated to give a blood serum level 
between 5-20 µg/mL which is considered an optimal physiologic dose. DPH was 
injected intraperitoneally in a volume ranging from 0.2 mL to 0.35 mL, based on 
the mouse body weight, 0.1 mL per 10 g of weight.  DPH stock was prepared by 
dissolving 55 mg of Dilantin in 10 ml of 0.01 N NaOH (Sigma Chemical Co). The 
DPH dose was determined in the Chatot laboratory based on observations of 
growth retardation and skeletal abnormalities in embryos at18 days of gestation 
similar to those observed in the fetal hydantoin syndrome and associated with  
growth retardation (Wolter and Chatot, BSU Honor’s Thesis, 1994; Gonzales and 
Chatot, 1995 unpublished).  The same volume per weight dose was used to 
inject 0.01 N NaOH into mated female control mice to provide a baseline for 
expression of DNA pol δ in 2-cell embryos at G1 and S phase during the 2
nd cell 
cycle.   
Embryo Isolation and Fixation 
NSA pregnant female mice were sacrificed by CO2  asphyxiation and 
cervical dislocation (BSU IACUC protocol # 91855-3 approved through 6/3/2012) 
at time points to determined ensure the collection of embryos at G1 and S phase 26 
 
of the 2
nd  cell cycle.  The time points were determined assuming that the 
fertilization occurred at the midnight of the day of mating.  For G1 of the second 
cell cycle the collections were performed at 24 hours post-fertilization (hpf).  G1 
of the second cell cycle time point was determined after the observation of the 
transition of the embryo from 1-cell to 2-cell, which happened 24 hours after the 
assumed time of fertilization.  Late S phase time point was 7 hours later at 31 
hpf, just 1 hour before G2 of the second cell cycle (Tolle and Chatot, 2009).   
Sacrificed females were dissected to obtain oviducts to isolate embryos.  
Oviducts were collected and placed in a culture dish with 0.9% of sterile saline 
solution (0.9 gm NaCl per 100 mL Milli-Q water). Embryos were flushed from 
oviducts using warm Hanks Balanced Salt Solution with 0.4% Bovine Serum 
Albumin (HBSS+BSA; Sigma Chemical Co.) and a 1 mL syringe with a 30 gauge 
blunt tip needle.  Isolated embryos were washed 3 times in HBSS+BSA, fixed in 
a 50 µl drop with 4% paraformaldehyde in Phosphate Buffered Saline (PBS) for 1 
hour at room temperature and then overlaid with CZB medium (for recipe, see 
Chatot et al., 1989) washed light mineral oil (Sigma Chemical, Co.). 
Immunofluorescence 
Embryo fixation was followed by two washes with HBSS+2% BSA to 
remove the remains of the paraformaldehyde, then embryos were permeabilized 27 
 
with 0.5% Triton X-100 in HBSS+0.8% BSA for 30 minutes to help antibodies 
enter into the cells.  Embryos were blocked by placing them in a 50 µl drop of 
Alexa Fluor Image Enhancer (Invitrogen, Carlsbad, CA) for 1 hour at room 
temperature to prevent non-specific staining and to reduce the background.  The 
embryos were stained with a primary antibody raised against DNA pol δ (catalytic 
subunit), rabbit anti-DNA pol δ (Catalog # sc-10784, Santa Cruz Biotechnologies, 
Santa Cruz, CA) (diluted 1:50 in Normal Goat Serum blocking solution in PBS; 
Invitrogen), for 1 hour at room temperature or overnight at 4
oC, then washed 3 
times for 5 minutes in HBSS+0.1% BSA+0.1% Tween-20 to remove non-specific 
binding from the primary antibody incubation.   The embryos were then incubated 
in a goat anti-rabbit IgG secondary antibody conjugated to Alexa Fluor 488 
(Invitrogen) (diluted 1:500 in blocking solution) in the dark for 1 hour at room 
temperature to detect the primary antibody and then blocked in Normal Goat 
Serum blocking solution for 20 minutes at room temperature.  Hoechst 33258 
(Sigma Chemical Co) (1 mg/mL stock diluted 1:100 in HBSS+ BSA) was used to 
stain the nucleus of the embryos to facilitate determining the localization of the 
DNA pol δ.   The incubation in Hoechst was made in the dark for 15 minutes 
followed by 3 washes in HBSS+0.1%BSA+0.1% Tween-20 to remove non-
specific binding.  Embryos were placed in a 10 µl drop of sterile Sigma Tissue 
Culture H2O on a poly-L-lysine coated coverslip (coverslips were soaked in a 28 
 
poly-L-lysine dilution of 1:10 from a 1 mg/ml stock, drained and allowed to dry) 
which allowed embryos to attach to the surface of the coverslip to retain them in 
the same position.  The H2O and BSA was removed to and was replaced with a 
fresh drop of H2O.  The poly-L-lysine coated coverslip was inverted over a drop 
of 20 µl of DABCO mounting medium (0.15 M 1,4-diazabicyclo [2.2.2] octane 
[DABCO], Sigma Chemical Co., in PBS:glycerol 1:9,) previously placed on a 
microscope slide; DABCO was used to prevent photobleaching during the 
imaging process.  The microscope slide and the coverslip were sealed with clear 
nail polish and air dried, then stored in the dark at 4  ˚C until analysis by confocal 
microscopy. 
The negative controls were prepared using the same staining protocol 
without the primary antibody, rabbit anti-DNA pol δ, but including the secondary 
antibody to assess the presence of background due to nonspecific staining. 
Staining with pre-immune/normal rabbit serum (diluted 1:50 in blocking solution) 
in place of the primary antibody was used to evaluate the specificity of the 
primary. 
Confocal Microscopy and Data Collection 
  Stained samples from DPH and NaOH vehicle control treated groups were 
visualized and scanned in the confocal microscope using the settings obtained 29 
 
after optimizing the scanning  of negative control embryos without the primary 
antibody raised against DNA pol δ (rabbit anti-DNA pol δ).  The settings were as 
follow: Scan mode: Stack, original data, 12 bit, Stack size: 2048 x 2048 x 35; 
Scaling 0.070 µm x 0.070 µm x 1.0 µm; Objective: Achroplan 63 x 0.95 W; Beam 
splitters: MBS: HFT 405/488/543, DBS1: NFT 490, NDD MBS: None.  
Wavelength: 488 nm - 5.1% and 405 - 10.1%; Filters: Ch1: LP 505, Ch2: BP 420-
480, Pinhole size: Ch1 - 142 µm; Ch2 - 142 µm.  To perform the densitometry the 
histogram tool from the Zeiss Paschal Software was used to define the perimeter 
of the embryos as well as the outer edges of the nuclear area.  The individual 
and average areas for the 40 embryos and 80 nuclei analyzed can be found in 
Appendix 1.  The nuclear and total areas of the slices of S phase NaOH embryos 
were slightly smaller than the other groups due to a peculiar angle of attachment 
of the embryos to the poly-L-lysine coated coverslips.  
Embryo images were saved using the Zeiss Paschal software package.  
Two-cell embryos from NaOH and DPH treatment groups in both G1 and S 
phase of the second cell cycle were analyzed for total embryo fluorescence as 
well as for nuclear fluorescence as described above.  Mean values were 
calculated for each of these intensity groups and the standard error of the mean 
(SEM) was determined. Total and nuclear mean fluorescence intensities of 
Dilantin and NaOH control groups at G1 and also at S phase were compared 30 
 
using a paired 2 tailed Student’s t-test (Microsoft Office Excel 2010).  
Experiments were performed using an n=40 embryos per stage/treatment for 
total fluorescence, and an n=80 nuclei per stage/treatment for nuclear 
fluorescence intensity.  Embryos were collected from 20 mice over multiple 
collection dates and staining was completed over multiple days for 
reproducibility. 
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RESULTS 
 
 
This research is a study of whether DPH, which alters patterns of Cyclin A 
expression (Tolle and Chatot, 2008), also affects the concentration of DNA pol  δ  
catalytic subunit in 2-cell preimplantation mouse embryos at G1 and S phases, 
thus delaying DNA synthesis (elongation during the 2
nd cell cycle).  The 
distribution and relative concentration of the DNA polymerase  δ  in 2-cell 
embryos at G1 and S phase of the 2
nd cell cycle in preimplantation mouse 
embryos was determined by observing patterns of fluorescent staining as well as 
measuring the relative fluorescence intensity levels emitted by the embryos 
probed with a rabbit anti-DNA pol δ catalytic subunit antibody.   
  Negative control embryos using pre-immune rabbit serum (Figure 6 A and 
B) or  lacking primary antibody (Figure 6 C and D ) demonstrated the lack of 
binding of the secondary antibody.  No nuclear staining was visualized in either 
negative control and cytoplasmic staining was minimal demonstrating the 
specificity of staining by the anti-DNA pol  δ  catalytic subunit antibody.  The 
presence and location of nuclei was displayed by Hoechst staining in each 
embryo. The negative control lacking the primary antibody was used for 
determination of settings for all other image collection (Figure 6 B).    32 
 
                
Figure 6.  Negative controls.  A. Nuclear staining of embryo with Hoechst 33258, B. 
Embryo without rabbit anti-DNA pol δ antibody; C. Nuclear staining of embryo with 
Hoechst 33258. D. Embryo probed with rabbit serum instead of anti-DNA pol δ antibody.  
The green halo around the embryo in D is the zona pellucida. Dilution of rabbit serum 
was 1:50; dilution of goat anti-rabbit IgG secondary antibody conjugated to Alexa Fluor 
488 was 1:500.  Images were collected using a 63X water immersion lens on a Zeiss 
Confocal Microscope and were exported from a slice in the Z stack that demonstrated 
staining in the middle of the nuclear region.   
 
For embryos stain with the anti-DNA pol δ antibody, photographic images 
were saved and analyzed by measuring the relative fluorescence intensity using 
Zeiss Pascal densitometry software. Fluorescence intensity was measured both 
in the complete embryo and in both nuclei of each embryo.  Fluorescence 33 
 
intensities were averaged for the 40 total embryos in each group as well 
as the 80 total nuclei per group. These data were analyzed for statistically 
significant differences between NaOH and DPH treated preimplantation embryos 
in G1 and S phase of the 2
nd cell cycle by performing two tailed t-tests.   
Analysis of G1 phase NaOH and DPH treated embryos 
G1 phase NaOH vehicle control treated embryos contain DNA pol δ as 
visualized by the presence of staining in the nucleus of the cell and minimal 
staining in the cytoplasm (Figure 7 A and B).  On the other hand, DPH treated G1 
phase embryos demonstrated little nuclear staining (Figure 7 C and D).  In 
support of these observations, relative total fluorescence levels of DNA pol δ at 
G1 in NaOH treated 2-cell mouse embryos were higher than in the embryos 
treated with DPH.  The mean total fluorescence intensity value of the embryos 
was 583 ± 80 and 251 ± 33 (mean values + Standard Error of the Mean; SEM) 
corresponding to NaOH and DPH treated embryos, respectively (Table 1; Figure 
8 B).  Total fluorescence values for NaOH treated embryos ranged from 2653 to 
67 relative intensity units respectively; and in DPH treated embryos from 822 to 
26, respectively.   The fluorescence levels of DNA pol δ in NaOH treated 
embryos at G1 was 57% higher than the DPH treated ones (P = 0.000157 
determined by student t-test; Table1). Equally, the nuclear mean fluorescence 
intensity levels of DNA pol δ at G1 in NaOH treated embryos was 654 ± 65, and 
234 ± 22 in DPH treated embryos (Table 1; figure 8 A).  Nuclear fluorescence 
intensity levels for NaOH treated embryos ranged from 3180 to 53; and for DPH 34 
 
treated embryos from 867 to 15, respectively.  In NaOH treated control embryos 
DNA pol δ fluorescence intensity was 64% higher than in DPH treated embryos 
(Table 1).  The difference between the groups was statistically highly significant 
(P = 3.71134 x 10
-9, determined by student t-test).  This data clearly 
demonstrates that the bulk of the total staining detected in both embryos is 
localized primarily to the nucleus since total fluorescence is not significantly 
different from nuclear fluorescence.  (Raw data for these samples can be found 
in Appendix 1.) 
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Figure 7. DNA pol δ localization in Preimplantation Mouse Embryos in G1 Phase of 
the Second Cell Cycle.  DNA pol δ total and nuclear fluorescence intensity in NaOH 
treated embryos was higher than DPH treated embryos during G1. A. nuclear staining of 
G1 phase NaOH treated embryos with Hoechst 33258, B. NaOH treated embryo stained 
with rabbit anti-DNA pol δ antibody; C. nuclear staining of a DPH treated embryo with 
Hoechst 33258. D. DPH treated embryo stained with anti-DNA pol δ antibody. The green 
halo around the embryo in D is the zona pellucida. Dilution of rabbit anti-DNA pol  δ 
primary antibody was 1:50; dilution of goat anti-rabbit IgG secondary antibody 
conjugated to Alexa Fluor 488 was 1:500.  Images were collected using a 63X water 
immersion lens on a Zeiss Confocal Microscope and were exported from a slice in the Z 
stack that demonstrated staining in the middle of the nuclear region.  Images were 
chosen to approximate mean fluorescence values. 
 
 
 
Table 1. Levels Of Nuclear and Total Fluorescence in DPH and NaOH Treated 
      Embryos During G1 and S Phase Of The Second Cell Cycle. 
 
Stage  Treatment  Total 
Fluorescence 
Mean ± SEM 
% of 
NaOH 
Control 
Nuclear 
Fluorescence 
Mean ± SEM 
% of 
NaOH 
Control 
G1 Phase  NaOH  583 ±80
a    654 ±65
b   
  DPH  251 ±33 
a  43  234 ±22 
b  36 
S Phase  NaOH  604 ±50
c    494 ±38
d   
  DPH  593 ±81
c  98  715 ± 68
d  144 
a Samples are statistically significantly different by student t-test; P = 0.000157 
b Samples are statistically significantly different by student t-test; P = 3.71134 x 10
-9 
c Samples are not statistically different by student t-test; P = 0.9087 
d Samples are statistically significantly different by student t-test; P = 0.0077 
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Figure 8. Levels of Nuclear and Total Embryo Fluorescence in G1 and S phase 
DPH and NaOH Treated Embryos.  A. Nuclear Fluorescence Intensities. Nuclear 
fluorescence levels of DNA pol δ in G1 NaOH embryos were significantly higher than in 
DPH embryos.  Nuclear fluorescence levels of DNA pol δ in S phase NaOH embryos 
were significantly lower than DPH embryos.  B. Total Fluorescence Intensities. Total 
fluorescence levels of DNA pol δ in G1 NaOH embryos were significantly higher than 
total fluorescence levels of DNA pol δ in G1 DPH treated embryos.  There was no 
significant difference between total fluorescence levels of NaOH and DPH treated 
embryos in S phase.    
   
B 
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Analysis of S Phase NaOH and DPH Treated Embryos 
DNA pol δ staining in the nuclei of NaOH treated vehicle control mouse 
embryos in S phase of the second cell cycle is diminished and cytoplasmic levels 
appear to increase (Figure 9 A and B).  In DPH treated embryos however, the 
levels of nuclear staining remain high and the antibody is more intense in 
discrete areas of the nucleus (Figure 9 C and D).  The mean of the total 
fluorescence intensity levels of DNA pol δ  in 2-cell embryos at S phase treated 
with NaOH was 604 ± 50 and for DPH treated 2-cell embryos was 593±81 (Table 
1; Figure 8 B). Total fluorescence values for NaOH treated embryos ranged from 
1453 to 235; and for DPH treated embryos from 2870 to 157, respectively.   The 
difference in total fluorescence between both groups was not statistically 
significant (P = 0.9087 by student t-test; Table 1).  However, the mean nuclear 
fluorescence of DNA pol δ between the NaOH (494±38) and DPH (715±68) 
treated groups was substantially different (P = 0.00773 by student t-test) with 
DPH treated embryo fluorescence levels being 144% of control NaOH treated 
embryos (Table 1; Figure 8 A).  The nuclear fluorescence values for NaOH 
treated embryos ranged from 1327 to 79 and for DPH treated embryos from 3318 
to 182.   
  Several clear patterns emerged from observations of both treatment groups.  
NaOH treated embryos in G1 of the second cell cycle generally demonstrated 
little cytoplasmic stain but very strong nuclear staining that localized to discrete 
modules in the nucleus (Figure 10 A); however, near the S phase/G2 transition, 
the nuclear staining diminished leaving almost a negative image of the nucleus 38 
 
and became slightly more intense in the cytoplasm (Figure 10 B).  DPH treated 
embryos showed very little staining for DNA Pol δ anywhere in the embryo (See 
Figure 7 D) but at the S phase/G2 transition, demonstrated a pattern similar to 
that of NaOH treated embryos in G1 with intense nuclear modules of DNA Pol δ 
staining (Figure 10 C).   
 
 
Figure 9.  DNA Pol δ localization in Preimplantation Mouse Embryos in S Phase of 
the Second Cell Cycle.  DNA pol δ nuclear fluorescence intensity in DPH treated 
embryos was higher than in NaOH embryos during S phase of the second cell cycle.  A. 
nuclear staining of S phase NaOH treated embryos with Hoechst 33258.  B. NaOH 
treated embryo stained with rabbit anti-DNA pol δ antibody; arrows indicate partial 
absence of DNA pol δ in the nucleus.  C. nuclear staining of a DPH treated embryo with 
Hoechst 33258. D. DPH treated embryo stained with anti-DNA pol δ antibody; arrows 
indicate higher levels of DNA pol δ in the nucleus compared with NaOH control embryos.  39 
 
Dilution of rabbit anti-DNA pol  δ primary antibody was 1:50; dilution of goat anti-rabbit 
IgG secondary antibody conjugated to Alexa Fluor 488 was 1:500.  Images were 
collected using a 63X water immersion lens on a Zeiss Confocal Microscope and were 
exported from a slice in the Z stack that demonstrated staining in the middle of the 
nuclear region.  Images were chosen to approximate mean fluorescence values. 
     
 
Figure 10. DNA pol δ displayed different patterns of staining during the G1 and S 
phase in response to the presence or absence of DPH.  A. NaOH treated embryo in 
G1.  B. NaOH treated embryo in S phase near the G2 transition.  C. DPH treated 
embryo in S phase near the G2 transition.  Images were collected using a 63X water 
immersion lens on a Zeiss Confocal Microscope and were exported from a slice in the Z 
stack that demonstrated staining in the middle of the nuclear region.  Images were 
chosen to highlight each specific pattern and may be more or less intense than the mean 
fluorescence intensity. 
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DISCUSSION 
 
 
DNA polymerase δ distribution and relative concentration levels in 2-cell 
embryos at G1 and S phase of the second cell cycle in vivo were determined by 
examining the patterns and levels of fluorescence of NaOH control and DPH 
treated embryos probed with a rabbit anti-DNA pol δ catalytic subunit specific 
antibody and a fluorescent secondary antibody by confocal microscopy. 
G1 NaOH treated embryos had higher levels of fluorescence compared 
with DPH treated embryos indicating that DPH alters the concentration of DNA 
pol δ in the cytoplasm and in the nucleus when compared with NaOH control 
embryos.  S phase NaOH and DPH treated embryos had similar total levels of 
fluorescence intensity, but different levels of nuclear fluorescence intensity.  S 
phase DPH treated embryos had higher nuclear levels of fluorescence compared 
with NaOH treated control embryos, indicating that the enzyme remains 
detectable in the nucleus of DPH treated embryos for a longer time than in 
control NaOH treated embryos. (See Figure 8)   41 
 
During G1 the cells prepare themselves to the transition to the S phase 
which is the stage of DNA replication (Lewin, 2004).  The low levels of DNA pol δ 
in G1 DPH treated embryos could affect their transition to S phase.  In contrast, 
late S phase DPH treated embryos exhibit high levels of nuclear fluorescence 
compared with NaOH controls (Table 1, Figure 8) and a particular pattern of 
fluorescence distribution within the nucleus (Figures 9 and 10) which appeared 
as dense nodules.    
The presence of DNA pol δ in the nucleus of DPH treated embryos for a 
longer time than NaOH treated control embryos could be due to stalling of DNA 
synthesis.  This could be attributed to at least two reasons.   One of the DPH 
intermediates, the arene oxide, is highly reactive and could cause damage to 
DNA pol δ reducing its efficiency of elongation.   In addition, the low levels of 
DNA pol δ observed in G1 (Figure 8) may not be sufficient to perform the 
elongation of lagging and leading strands early in the replication part of the cycle; 
although by the end of S phase, when the S phase samples were collected, the 
levels of DNA pol δ have increased. 
Pavlov and Shcherbakova (2010) proposed a new model in which DNA 
pol δ is responsible for the elongation of both leading and lagging strands.   If the 
presence of DNA pol δ in the nucleus of DPH treated embryos at the start of S 
phase is low, due either to synthesis or degradation problems in G1 or to any 
kind damage generated by the arene oxide intermediate product of the 42 
 
metabolism of DPH, then the elongation of the leading and lagging strands could 
be seriously compromised and the DNA synthesis would stall. 
   The DPH arene oxide could generate damage to the DNA pol δ catalytic 
subunit which contains DNA polymerase and exonuclease domains (Strickler, 
1985; Pavlov and Shcherbakova, 2010).  Damage to the polymerase and/or 
exonuclease domains could reduce the rate of polymerization, slowing the 
progression of the replication fork, which could explain the prolonged S phase 
observed by Blosser and Chatot (2003) in 2-cell embryos treated with DPH. 
Damage in the 3’-5’ exonuclease domain would decrease the proofreading 
accuracy of the replication process.   Reduction of 3’-5’ exonuclease activity of 
DNA pol δ could increase the rate of errors in the incorporation of nucleotides 
during DNA synthesis generating mismatches.  
    The DPH arene oxide metabolite, could generate direct damage to the 
DNA template itself (Strickler et al. 1985).  When the replication fork stalls due to 
a lesion in the DNA, DNA synthesis continues downstream of the lesion (Pavlov 
and Shcherbakova, 2010) and the gap is filled by TLS DNA polymerases.  
However, TLS DNA polymerases bypass lesions frequently generating mutations 
(Pavlov and Shcherbakova, 2010).  If the DPH arene oxide generates 
substantive DNA damage, then the influence of TLS DNA polymerases would be 
significant and the rate of mutations would be higher, which could explain some 
of the growth related anomalies generated by DPH observed in FHS.  43 
 
  The low levels of DNA pol δ observed in G1 DPH treated embryos 
compared with NaOH control embryos during the second cell cycle (Figure 8) 
could be due to direct damage to pol δ as explained before.  DNA synthesis 
starts in the transition between G1 and S phase (Lewin, 2004).  Low levels of pol 
δ during this transition could delay or inhibit the elongation of the leading and 
lagging strands during DNA synthesis. This scenario could be one of reasons 
that explains the extended S phase observed by Blosser and Chatot (2003) in 
DPH treated embryos in vitro during the second cell cycle.    
  However, after the potential damage of Pol δ by DPH arene oxide, what 
mechanisms could generate the observed decrease in the amount of Pol δ in 
G1?  There are different situations that could explain this decrease but probably 
the decline is due to a combined effect of all of them.   
The low levels of Pol δ in G1, probably altered by the arene oxide, could 
be due degradation of the enzyme.  Determination of the levels of degradation of 
Pol δ in DPH treated embryos could be inferred from detection of Pol δ 
ubiquitination using a specific antibody raised against ubiquitin in Western blots 
of immunoprecipitated Pol δ catalytic subunit in early G1.  Pulse – chase 
experiments using radioactive labeling of protein synthesis in second cell cycle 
G1 embryos treated with either NaOH or DPH followed by immunoprecipitation 
and electrophoretic/autoradiographic analysis could also address this issue. 
Embryo and maternal mRNAs could also be affected by DPH arene oxide 
during G1 in DPH treated embryos (Strickler et al. 1985) and therefore, the 44 
 
translation of Pol δ could be decreased substantially.  This could be examined 
using RT-PCR to determine if there are changes in the levels of RNA specific for 
the Pol δ catalytic subunit in DPH treated embryos compared with NaOH treated 
controls at various times in G1 and S phase.  These changes are occurring at the 
time of zygotic gene activation and maternal RNA degradation so it is possible 
that reduced protein levels is a reflection of RNA damage and reduced 
translation. 
  Tolle and Chatot (2009) reported that G1 DPH treated embryos exhibited 
high levels of cyclin A compared with NaOH embryos during the second cell 
cycle.  High levels of cyclin A inhibited Pol α-dependent initiation of SV40 DNA 
replication (Voitenleitner et al. 1997), thus DNA synthesis initiation in S phase 
DPH treated embryos could be affected due to high levels of cyclin A during G1 
transition to S phase.  Similarly, Bashir et al. (2000) indicates that the activation 
of DNA Pol δ-dependent elongation machinery is performed by cyclin A in a 
parvovirus model in vitro.  Tolle and Chatot  (2009) reported that cyclin A is 
significantly reduced in DPH embryos in S phase of the second cell cycle. Thus 
high levels of cyclin A in G1, low levels of cyclin A in S phase plus low levels of 
Pol δ observed in G1 in DPH embryos (Figure 8) can all contribute to inhibiting 
the initiation of replication as well as the elongation of lagging and leading 
strands during the DNA synthesis.  This argument could explain the long S phase 
in DPH treated embryos during the second cell cycle as observed by Blosser and 
Chatot (2003) and as supported by our data in vivo that demonstrates DNA pol δ 45 
 
in the nucleus in DPH treated embryos at later times than what is seen in NaOH 
treated controls. 
The data generated during our experiments suggest that the DNA 
synthesis of 2-cell embryos treated with DPH in vivo could be seriously affected 
by damage to DNA pol δ during G1 and/or S phase of the second cell cycle.  Our 
data corroborate and explain the blocking of significant numbers of 2-cell 
embryos during the S phase of the second cell cycle when treated with DPH 
reported by Blosser and Chatot (2003) and suggest explanations for the 
occurrence of FHS in the offspring of pregnant women taking DPH. 
A number of future experiments could shed light on these issues.   For 
example, the characterization of alterations to DNA pol δ by DPH would help to 
determine if specific damage was done to the enzyme and if it is localized to the 
catalytic subunit.  The performance of DNA pol δ activity assays would confirm a 
reduction in the rate of polymerization by the Pol δ enzyme in the presence of 
DPH compared with NaOH controls.  
   Additional monitoring of the levels of expression of Pol δ during the G1 
and S phases in DPH and NaOH control treated embryos during the second cell 
cycle would shed additional light on the exact timing of pol δ decreases and 
increases. Collecting embryos at different time points during the transition 
between these two phases would be particularly interesting. This information 
could help determine the time when Pol δ is most affected by the DPH arene 
oxide.  The patterns of altered expression of Pol δ in DPH embryos could be 46 
 
contrasted with cyclin A altered patterns of expression together with 
determination of levels of activity in Pol δ DPH treated embryos. This information 
would lead to a better understanding of DNA synthesis in DPH treated embryos 
during the second cell cycle.  
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APPENDIX 1 
 
 
Total 
Fluorescence  G1 NaOH 
     
Embryo No.  Mean Intensity 
Standard 
Deviation  Area 
Slice 
No. 
1  728.94  277.57  3100.96  19/32 
2  933.69  324.88  3093.49  17/30 
3  1007.19  293.55  3045.4  18/33 
Again (2) 4  1294.14  619.68  3852.89  28/46 
5  385  160.76  4484.89  18/28 
6  845.37  304.25  4041.4  20/33 
7  1119.59  621.11  4900  25/45 
8  1350.15  610.56  4590.64  25/45 
9  812.66  375.24  5267.93  18/31 
10  212.08  194.27  4663.76  18/32 
11  620.97  458.68  4303.25  15/42 
12  263.82  299.37  4314.87  20/31 
13  86.57  94.3  4308.46  17/31 
14  255.99  115.54  4556.6  19/30 
15  372.4  309.41  4538.79  31/12 
16  288.19  139.03  4575.32  32/11 
17  2652.79  984.41  4892.22  26/40 
18  1148.57  588.77  4763.9  13/26 
19  1111.38  507.86  5548.17  14/25 
20  239.52  159.25  5503.67  18/9 
21  320.35  191.17  5789.4  18/9 
22  370.83  122.75  4395.54  13/25 
23  180.08  130.44  5268.26  24/12 
24  67.43  67.24  5633.73  13/25 
25  81.32  72.85  5069.41  13/26 
26  346.59  203.17  4614.01  13/25 
27  216.17  173.99  4550.08  16/31 
28  419.09  281.89  3796.21  18/31 52 
 
29  947.83  612.93  3647.85  16/34 
30  1132.77  569.8  3805.48  19/38 
31  475.22  377.61  3705.02  16/34 
32  383.85  179.78  3910.95  18/32 
33  787.63  275.05  3663.5  16/32 
34  521.14  218.98  3888.23  20/31 
35  340.8  207.72  3018.38  13/30 
36  119.78  115.94  3868.88  14/28 
37  236.2  79.87  3737.16  17/30 
38  128.78  120.86  3451.95  15/29 
39  244.81  92.67  3859.13  13/28 
40  277.02  104.49  3486.95  13/28 
 
Total 
fluorescence            G1 DPH 
     
Embryo No.  Mean Intensity  Standard Deviation  Area 
Slice 
No. 
1  155.64  45.97  5374.13  19/41 
2  217.54  93.69  5223.88  18/37 
3  143.36  39.21  4645.43  16/30 
4  197.07  63.95  4476.82  14/30 
5  174.02  46.46  3607.22  15/30 
6  150.61  40.93  3632.92  15/29 
7  822.06  395.06  4395.13  33/52 
8  156.01  177.3  3772.02  21/37 
9  154.6  43.35  4380.82  18/38 
10  27.98  41.33  5692  17/34 
11  28.99  43.76  5020.06  25/12 
12  46.03  63.37  5220.97  15/30 
13  95.36  99.86  4474.57  16/33 
14  56.03  63.87  4764.28  29/12 
15  25.68  38.21  5063.58  24/11 
16  68.31  90.75  4231.45  17/8 
17  384.85  235.11  4504.98  16/31 
18  750.69  463.4  4080.87  27/47 
19  260.71  164.8  5484.95  14/24 
20  211.45  153.56  4753.35  14/21 
21  368.07  229.64  4426.4  14/23 
22  131.52  107.42  4968.66  18/10 
23  211.78  135.13  4653.18  18/10 
24  372.53  225.1  4972.78  21/12 
25  147.56  126.64  5309.17  22/12 53 
 
26  716.59  530.22  4162  15/25 
27  792.85  552.9  4195.36  14/23 
28  237.84  202.92  4807.78  13/21 
29  298.76  187.63  5631.33  20/12 
30  256.24  167.47  4561.4  13/21 
31  330.09  183.17  4169.96  18/9 
32  478.54  220.8  4253.36  15/21 
33  259.1  184.25  4656.96  18/10 
34  229.95  155.38  4317.79  21/11 
35  363.17  150.36  4789.03  15/23 
36  134.36  117.38  5112.07  20/12 
37  184.42  128.42  4740.72  19/11 
38  140.94  123.64  43458.66  21/12 
39  141.99  105.82  3348.09  18/10 
40  131.33  98.69  4021.57  14/21 
 
Total 
Fluorescence  S NaOH 
     
Embryo No.  Mean Intensity 
Standard 
Deviation  Area 
Slice 
No. 
1  301.57  211.96  3444.96  14/21 
2  241  144.85  2942.33  21/11 
3  1308.8  1166.33  3040.42  27/12 
4  379.31  133.56  2087  23/42 
5  1453.14  707.3  2173.48  30/58 
6  418.52  187.41  2256.67  26/52 
7  391.77  248.44  1944.37  22/48 
8  625.77  259.22  2313.7  36/12 
9  634.66  324.33  3434.85  27/12 
10  434.17  219.5  3290.43  20/6 
11  285.38  196.95  3651.73  26/10 
12  394.31  350.02  3125.06  13/25 
13  385.72  129.4  2744.29  14/27 
14  336.52  175.16  3756.3  27/12 
15  766.31  494.48  3374.34  13/28 
16  234.69  176.61  3080.66  27/11 
17  383.9  110.96  2656.08  14/27 
18  275.33  169.17  2297.96  29/11 
19  254.14  165.41  3125.47  25/11 
20  628.35  355.85  2829.88  13/26 
21  408.29  186.86  2486.37  23/11 
22  278.82  128.04  3049.69  14/25 54 
 
23  337.61  192.11  2552.36  23/9 
24  315.02  160.3  2799.67  15/30 
25  310.12  146.92  2985.25  14/27 
26  672.09  233.01  3530.75  13/22 
27  950.64  270.02  4313.81  15/25 
28  700.53  324.85  4644.97  13/21 
29  871.58  417.83  3464.01  19/8 
30  775.68  355.16  4274.98  19/8 
31  774.82  290.82  3699.16  16/9 
32  810.85  352.54  4016.89  18/8 
33  804.81  296.12  3957.87  14/27 
34  654.6  272.45  3616.43  16/11 
35  962.1  667.38  4129.52  15/25 
36  1285.21  561.59  4407.02  15/25 
37  882.48  327.4  4067.75  13/22 
38  799.69  331.91  4236.21  18/9 
39  758.55  311.77  3897.54  14/25 
40  682.4  346.35  4192.62  13/24 
 
 
Total 
Fluorescence            S DPH 
     
Embryo No.  Mean Intensity  Standard Deviation  Area 
Slice 
No. 
1  234.43  141.48  5154.61  18/10 
2  330.83  125.61  4415.12  17/9 
3  593.56  203.36  4344.76  15/24 
4  235.66  107.89  4217.97  17/10 
5  531.91  128.19  4453.38  21/12 
6  495.33  113.09  4222.96  21/12 
7  1767.5  519.29  4833.65  23/35 
8  448.84  147.75  4665.18  13/21 
9  253.62  85.23  4439.6  17/9 
10  645.35  169.98  4214.6  17/25 
11  491.61  184.51  4645.74  20/20 
12  476.75  196.42  4104.93  17/9 
13  301.73  129.55  4653.82  19/11 
14  1562  626.3  4239.37  21/28 
15  316.04  118.69  4642.67  18/12 
16  398.14  148.18  5090.82  18/12 
17  455.81  131.07  5206.04  19/12 55 
 
18  2869.62  584.84  4767.41  23/37 
19  584.47  225.69  4865.57  14/19 
20  156.69  124.31  4095.52  15/9 
21  273.25  108  4733.27  13/19 
22  525.07  199.81  4912.5  13/19 
23  535.28  175.18  4843.97  13/19 
24  538.3  164.27  5540.28  15/23 
25  410.5  125.35  4913.57  18/11 
26  311.59  99.82  4548.62  13/19 
27  517.97  145.74  4247.66  13/20 
28  470.15  165.46  4493.95  16/9 
29  248.49  107.97  4594.54  18/12 
30  439.87  82.17  4640.09  19/11 
31  808.5  342.73  4710.62  13/21 
32  1589.8  680.32  4654.93  17/25 
33  489.9  193.39  4736.17  14/20 
34  485.95  150.01  4692.38  19/12 
35  315.72  112.32  4762.84  18/12 
36  525.33  179.1  4403.35  20/12 
37  417.2  228.5  4954.88  17/23 
38  744.07  230.14  4078.51  23/8 
39  401.18  183.66  3958.42  19/12 
40  510.96  216.66  4535.47  14/22 
 
 
Nuclear 
Fluorescence  G1 NaOH 
     
Embryo No.  Mean Intensity  Standard Deviation  Area 
Slice 
No. 
1  895.99  313.96  238.25  19/32 
 
977.19  332.06  193.4  19/32 
2  1203.42  427.7  199.85  17/30 
 
1218.56  427.24  207.87  17/30 
3  1214.35  376.78  247.75  18/33 
 
1220.49  389.84  198.85  18/33 
4  1195.5  527.79  249.62  28/46 
 
1295.51  544.14  254.3  28/46 
5  537.84  159.92  209.44  18/28 
 
340.25  124.39  207.38  18/28 
6  885.19  275.53  252.67  20/33 
 
1055.54  303.71  225.7  20/33 56 
 
7  1522.37  576.98  298.71  25/45 
 
1119.9  462.01  287.49  25/45 
8  1609.5  532.71  272.34  25/45 
 
1462.13  557.91  293.84  25/45 
9  1108.47  411.82  360.64  18/31 
 
1210.94  446.88  308.79  18/31 
10  258.52  206.34  358.15  18/32 
 
205.23  184.48  347.91  18/32 
11  656.46  440.2  285.87  15/42 
 
610.46  416.03  276.15  15/42 
12  306.7  310.7  250.46  20/31 
 
257.49  293.32  302.43  20/31 
13  85.52  91.12  215.08  17/31 
 
87.56  92.04  208.15  17/31 
14  319  134.17  246.6  19/30 
 
265.9  110.51  227.41  19/30 
15  531.24  345.48  260.8  31/12 
 
374.7  343.03  232.4  31/12 
16  417.11  132.6  281.88  32/11 
 
321.88  133.17  242.51  32/11 
17  3179.77  628.27  304.52  26/40 
 
2866.18  905.77  282.49  26/40 
18  917.8  338.12  292.16  13/26 
 
1297.8  381.29  272.16  13/26 
19  1508.61  516.11  309.08  14/25 
 
1035.61  367.56  292.22  14/25 
20  319.15  124.63  251.38  18/9 
 
213.26  116.26  225.75  18/9 
21  445.84  162.11  225.19  18/9 
 
400.74  159.52  234.89  18/9 
22  392.13  103.28  217.99  13/25 
 
340.58  66.72  200.94  13/25 
23  265.63  106.01  256.8  33/12 
 
336.16  151.92  274.1  33/12 
24  183.49  105.7  222.7  13/25 
 
52.53  48.06  257.11  13/25 
25  192.6  105.16  238.82  13/26 
 
120.29  75.55  200.19  13/26 
26  340.29  192.09  231.57  13/25 
 
379.53  202.67  249.81  13/25 
27  239.2  175.64  271.56  16/31 
 
240.85  176.31  236.57  16/31 
28  412.13  265.06  164  18/31 57 
 
 
467.29  280.61  178.49  18/31 
29  885.56  589.34  145.33  16/34 
 
948.59  564.42  157.7  16/34 
30  1194.16  524  216.99  19/38 
 
1456.72  602.29  200.85  19/38 
31  435.57  306.38  207.45  16/34 
 
438.52  304.69  163.1  16/34 
32  372.19  170.67  168.26  18/32 
 
377.96  169.48  144.85  18/32 
33  877.48  309.21  206.25  16/32 
 
734.74  251.25  181.76  16/32 
34  477.05  188.1  140.84  20/31 
 
566.9  212.78  157.7  20/31 
35  397.9  204.25  128.51  13/30 
 
301.1  176.05  138.3  13/30 
36  110.41  101.66  191.43  14/28 
 
110.81  101.26  169.87  14/28 
37  231.82  71.78  179.04  17/30 
 
238.38  73.39  165.59  17/30 
38  125.49  109.49  165  15/29 
 
97.78  95.94  164.03  15/29 
39  234.22  82.06  188.67  13/28 
 
246.12  86.07  170.32  13/28 
40  272.6  93.28  182.45  13/28 
 
237.5  83.76  206.1  13/28 
 
 
Nuclear 
fluorescence  G1 DPH 
      Embryo No.  Mean Intensity  Standard Deviation  Area  Slice No. 
1  143.81  38.52  261.8  19/41 
 
151.76  40.97  266.23  19/41 
2  183.37  53.75  192.73  18/37 
 
172.24  50.48  207.72  18/37 
3  137.86  32.68  224.37  16/30 
 
139.38  33.2  225.9  16/30 
4  191.51  59.26  216.05  14/30 
 
199.3  61.58  211.63  14/30 
5  166.07  40.16  160.8  15/30 
 
161.92  38.82  181.2  15/30 
6  143.31  33.18  193.36  15/29 58 
 
 
142.59  32.81  201.65  15/29 
7  709.44  324.63  206.89  33/52 
 
710.22  322.34  209.2  33/52 
8  173.74  180.98  214.47  21/37 
 
165.73  178.35  227.83  21/37 
9  135.45  22.13  220.08  18/38 
 
138.45  22.71  227.18  18/38 
10  20.16  29.69  206.05  17/34 
 
14.89  25.19  230.98  17/34 
11  30.77  38.13  229.01  25/12 
 
23.96  33.23  253.8  25/12 
12  43.39  51.56  199.13  15/30 
 
31.62  43.66  201.24  15/30 
13  103.51  93.8  227.68  16/33 
 
113.15  98.35  210.6  16/33 
14  30.77  36.86  186.46  29/12 
 
27.88  35.02  163.56  29/12 
15  26.56  36.7  176.24  24/11 
 
25.22  35.31  177.24  24/11 
16  37.95  51.03  155.55  17/8 
 
66.69  69.66  173.28  17/8 
17  467.63  239.87  150.37  16/31 
 
411.9  225.97  159.08  16/31 
18  670.36  387.88  163.28  27/47 
 
711.33  394.63  156.69  27/47 
19  200.9  126.19  203.81  14/24 
 
200.7  125.33  225.75  14/24 
20  198.58  117.14  199.33  14/21 
 
188.2  114.03  174.25  14/21 
21  309.63  170.4  187.16  14/23 
 
225.53  145.97  181.75  14/23 
22  140.81  101.11  205.1  18/10 
 
109.09  88.03  206.63  18/10 
23  173.25  110.65  228.02  18/10 
 
139.76  100.95  204.71  18/10 
24  355.32  194.07  243.82  21/12 
 
314.41  177.43  240.64  21/12 
25  154.93  134.88  207.95  22/12 
 
132.42  112.11  183.95  22/12 
26  801.61  494.48  160.66  15/25 
 
590.4  423.85  169.61  15/25 
27  867.39  519.32  181.71  14/23 
 
737.72  469.69  161.76  14/23 59 
 
28  290.29  203.53  225.88  13/21 
 
379.18  241.38  194.8  13/21 
29  261.02  158.83  164.94  20/12 
 
400.42  214.16  182.84  20/12 
30  224.54  140.31  154.99  13/21 
 
239.68  144.85  157.42  13/21 
31  269.72  145.46  157.4  18/9 
 
253.55  142.7  170.62  18/9 
32  344.29  114.67  245.04  15/21 
 
395.5  128.68  228.49  15/21 
33  207.78  125.36  213.9  18/10 
 
292.96  163.68  225.21  18/10 
34  234.01  135.91  258.41  21/11 
 
216.84  130.98  206.93  21/11 
35  307.27  110.4  168.02  15/23 
 
285.06  104.12  160.18  15/23 
36  67.97  55.61  172.39  20/12 
 
138.23  77.13  195.34  20/12 
37  199.01  119.91  209.46  19/11 
 
240.47  107.72  212.79  19/11 
38  62.98  54.47  189.92  21/12 
 
156.95  95.89  194.64  21/12 
39  174.48  89.52  183.68  18/10 
 
192.91  106.67  226.87  18/10 
40  101.49  78.36  249.7  14/21 
 
138.68  71.69  243.98  14/21 
 
 
Nuclear 
Fluorescence  S  NaOH 
     
Embryo No.  Mean Intensity  Standard Deviation  Area 
Slice 
No. 
1  225.51  71.92  208.7  14/21 
 
180.04  52.4  208.82  14/21 
2  127.79  40.2  190.53  21/11 
 
147.88  42.29  154.91  21/11 
3  480.65  69.93  135.94  27/12 
 
501.27  69.84  149.65  27/12 
4  307.43  103.75  80.83  23/42 
 
310.79  105.74  86.72  23/42 
5  1326.56  646.3  122.61  30/58 60 
 
 
1206.32  614.91  117.66  30/58 
6  335.33  147.69  136.15  26/52 
 
343.12  149.41  126.03  26/52 
7  284.1  197.01  108.49  22/48 
 
248.76  185.07  136.9  22/48 
8  431.75  182.09  131.47  36/12 
 
418.46  177.09  134.66  36/12 
9  354.26  179.35  184.81  27/12 
 
765.34  267.51  184.96  27/12 
10  291.58  126.45  161.42  20/6 
 
318.37  134.52  156.54  20/6 
11  250.69  129.49  184.67  26/10 
 
139.75  100.72  192.66  26/10 
12  265.58  211.24  175.68  13/25 
 
229.37  191.6  164.47  13/25 
13  319.93  99.35  145.63  14/27 
 
294.4  90.29  131.24  14/27 
14  297.27  122.69  195.69  27/12 
 
326.81  132.51  236.5  27/12 
15  255.09  171.52  145.93  13/28 
 
770.76  291.03  170.67  13/28 
16  78.81  74.33  141.77  27/11 
 
148.47  94.26  161.08  27/11 
17  314.54  82.22  194.17  14/27 
 
312.34  79.13  193.4  14/27 
18  144.05  99.7  163.24  29/11 
 
148.32  102.78  140.81  29/11 
19  139.01  97.37  169.35  25/11 
 
230.13  115  170.42  25/11 
20  495.88  287.79  182.86  13/26 
 
548.44  300.04  185  13/26 
21  308.1  139.64  167.78  23/11 
 
252.91  123.88  188.58  23/11 
22  208.48  97.8  167.64  14/25 
 
193.98  88.92  156.36  14/25 
23  215.28  111.65  127.81  23/9 
 
163.92  98.99  143.71  23/9 
24  238.22  120.47  175.71  15/30 
 
213.15  11.4  186.87  15/30 
25  208.87  108.86  168.74  124/27 
 
209.14  105.96  177.79  14/27 
26  638.77  199.51  157.59  13/22 
 
650.36  204.66  179.8  13/22 61 
 
27  890.13  222.44  199.24  15/25 
 
907.46  224.68  181.29  15/25 
28  813.69  274.59  209.76  13/21 
 
528.12  220.77  200.72  13/21 
29  745.18  306.21  162.47  19/8 
 
855.5  356.41  137.79  19/8 
30  650.37  268.31  191.13  19/8 
 
628.48  262.36  184.69  19/8 
31  656.2  232.42  152.21  16/9 
 
556.31  224.06  148.42  16/9 
32  643.9  293.67  190.09  18/8 
 
628.53  267.14  183.45  18/8 
33  701.07  256.25  136.2  14/27 
 
711.75  252.66  138.33  14/27 
34  611.35  223.33  200.55  16/11 
 
636.6  268.94  166.87  16/11 
35  658.63  354.57  111.64  15/25 
 
1314.01  496.86  85.25  15/25 
36  1187.96  489.11  114.62  15/25 
 
1280.03  508.51  100.74  15/25 
37  804.98  271.77  98.64  13/22 
 
853.27  275.53  104.1  13/22 
38  867.66  278.23  153.61  18/9 
 
689.21  254.06  166.94  18/9 
39  553.1  226.86  121.07  14/25 
 
696.72  254.63  114.25  14/25 
40  863.36  360.53  147.52  13/24 
 
760.4  334.62  150.62  13/24 
 
 
Nuclear 
fluorescence  S DPH 
      Embryo No.  Mean Intensity  Standard Deviation  Area  Slice No. 
1  462.14  130.75  252.34  18/10 
 
425.1  132.39  232.7  18/10 
2  420.53  95.8  220.65  17/9 
 
395.4  94.69  208.51  17/9 
3  896.6  207.04  270.86  15/24 
 
785.8  195.16  244.71  15/24 
4  360.71  111.86  204.87  17/10 
 
351.59  105.99  233.45  17/10 62 
 
5  646.93  117.15  245.02  21/12 
 
662.93  134.87  233.23  21/12 
6  601.94  104.1  316.46  21/12 
 
600.66  104.55  272.67  21/12 
7  2389.29  5215.06  245.38  23/35 
 
2333.01  499.74  264.55  23/35 
8  528.22  127.45  255.01  13/21 
 
482.87  117.92  190.96  13/21 
9  331.78  77.61  275.6  17/9 
 
304.63  77.57  269.42  17/9 
10  761.91  164.14  265.31  17/25 
 
728.91  157.86  296.44  17/25 
11  643.87  137.22  315.97  20/12 
 
598.84  141.04  339.05  20/12 
12  748.95  186.7  188.14  17/9 
 
326.96  101.47  240.46  17/9 
13  390.3  95.81  272.93  19/11 
 
371.59  95.79  269.52  19/11 
14  2532.52  555.5  223.33  21/28 
 
1546.31  469.92  254.51  21/28 
15  364.66  95.1  269.2  18/12 
 
338.93  90.77  307.77  18/12 
16  461.01  116.82  334.3  18/12 
 
446.71  113.69  294.12  18/12 
17  544.05  127.13  218.26  19/12 
 
470.52  113.13  242.85  19/12 
18  3317.54  536.33  312.86  23/37 
 
3205.02  546.81  279.23  23/37 
19  721.19  189.64  378.21  14/19 
 
733  180.4  291.06  14/19 
20  194.73  66.62  244.35  15/9 
 
182.34  64.03  261.88  15/9 
21  334.81  90.89  318.2  13/19 
 
299.47  86.28  258.98  13/19 
22  785.34  191.72  287.35  13/19 
 
624.48  171.9  262.32  13/19 
23  696.85  185.18  22.5  13/19 
 
543.6  156.26  208.84  13/19 
24  621.76  116.66  367.19  15/23 
 
565.88  112.68  321.98  15/23 
25  481.15  116.24  374.7  18/11 
 
443.84  116.84  348.71  18/11 
26  354.04  101.54  232.44  13/19 63 
 
 
331.71  100.57  306.17  13/19 
27  608.59  150.86  407.99  13/20 
 
526.99  126.96  341.54  13/20 
28  483.59  127.12  229.83  16/9 
 
512.48  127.75  233.08  16/9 
29  351.32  108.46  283.19  18/12 
 
320.77  96.95  281.07  18/12 
30  482.13  86.76  235.71  19/11 
 
477.79  86.47  258.58  19/11 
31  938.15  290.36  323.89  13/21 
 
859.92  367.97  334.4  13/21 
32  1682.72  502.69  271.42  17/25 
 
1702.21  537.68  288.56  17/25 
33  534.71  180.3  245.78  14/20 
 
507.57  173.81  231.34  14/20 
34  620.58  146.27  312.65  19/12 
 
569.35  145.41  6330.31  19/12 
35  385.25  121.4  290.26  18/12 
 
376.55  119.53  288.15  18/12 
36  712.92  208.34  267.07  20/12 
 
710.51  207.93  263.19  20/12 
37  428.22  222.85  185.15  17/23 
 
462.96  342.05  206.41  17/23 
38  930.11  225.15  351.79  23/8 
 
828.62  210.85  326.23  23/8 
39  684.31  211.78  250.85  19/12 
 
579.35  222.68  331.95  19/12 
40  558.48  185.23  261.57  14/22 
 
694.01  214.12  274.04  14/22 
 
 